Pedro Nuno Palma

Pedro Nuno Palma

Auto-generated profile, based on publicly available information

Pedro Nuno Palma

Departamento de Química, Centro Química Fina e Biotecnologia, Faculdade de Ciências e Tecnologia, Universidade Nova de Lisboa, Caparica, Portugal

Research Focus & Metrics

Academic Career Length

34Years (1993-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
24 September 2007 in CNS Drug Reviews
Verified
Journal Article
Open access
PDF file
MBMaria João Bonifácio
Maria João Bonifácio
PPP. Nuno Palma
P. Nuno Palma
LALuís Almeida
Luís Almeida
PSPatrício Soares‐Da‐Silva
Patrício Soares‐Da‐Silva
Parkinson's disease (PD) is a neurological disorder characterized by the degeneration of dopaminergic neurons, with consequent reduction in striatal dopamine levels leading to characteristic motor symptoms. The most effective treatment for this disease continues to be the dopamine replacement therapy with levodopa together with an inhibitor of aromatic amino acid decarboxylase (AADC). The efficacy of this therapy, however, decreases with time and most patients develop fluctuating responses and dyskinesias. The last decade showed that the use of catechol‐O‐methyltransferase inhibitors as adjuvants to the levodopa/AADC inhibitor therapy, significantly improves the clinical benefits of this therapy.The purpose of this article is to review the current knowledge on the enzyme catechol‐O‐methyltransferase (COMT) and the role of COMT inhibitors in PD as a new therapeutic approach to PD involving conversion of levodopa to dopamine at the target region in the brain and facilitation of the continuous action of this amine at the receptor sites. A historical overview of the discovery and development of COMT inhibitors is presented with a special emphasis on nebicapone, presently under clinical development, as well as entacapone and tolcapone, which are already approved as adjuncts in the therapy of PD. This article reviews human pharmacokinetic and pharmacodynamic properties of these drugs as well as their clinical efficacy and safety.

24 March 2010 in Journal of Medicinal Chemistry
Verified
Journal Article
Closed access
LKLászló E. Kiss
László E. Kiss
HFHumberto S. Ferreira
Humberto S. Ferreira
LTLeonel Torrão
Leonel Torrão
MBMaria João Bonifácio
Maria João Bonifácio
PPP. Nuno Palma
P. Nuno Palma
DLDavid A. Learmonth
David A. Learmonth

1 February 2015 in Neuropharmacology
Verified
Journal Article
Closed access
SHSimon Hebeisen
Simon Hebeisen
NPNuno Pires
Nuno Pires
ALAna I. Loureiro
Ana I. Loureiro
MBMaria João Bonifácio
Maria João Bonifácio
NPNuno Palma
Nuno Palma
PSPatrício Soares-Da-Silva
Patrício Soares-Da-Silva

21 January 2013 in British Journal of Clinical Pharmacology
Verified
Journal Article
Open access
PDF file
JRJosé Francisco Rocha
José Francisco Rocha
LALuis Almeida
Luis Almeida
AFAmílcar Falcão
Amílcar Falcão
PPP. Nuno Palma
P. Nuno Palma
ALAna I. Loureiro
Ana I. Loureiro
PSPatrício Soares‐Da‐Silva
Patrício Soares‐Da‐Silva
Aims: The aim of this study was to assess the tolerability, pharmacokinetics and inhibitory effect on erythrocyte soluble catechol‐O‐methyltransferase (S‐COMT) activity following repeated doses of opicapone.Methods: This randomized, placebo‐controlled, double‐blind study enrolled healthy male subjects who received either once daily placebo or opicapone 5, 10, 20 or 30 mg for 8 days.Results: Opicapone was well tolerated. Its systemic exposure increased in an approximately dose‐proportional manner with an apparent terminal half‐life of 1.0 to 1.4 h. Sulphation was the main metabolic pathway. Opicapone metabolites recovered in urine accounted for less than 3% of the amount of opicapone administered suggesting that bile is likely the main route of excretion. Maximum S‐COMT inhibition (Emax) ranged from 69.9% to 98.0% following the last dose of opicapone. The opicapone‐induced S‐COMT inhibition showed a half‐life in excess of 100 h, which was dose‐independent and much longer than plasma drug exposure. Such a half‐life translates into a putative underlying rate constant that is comparable with the estimated dissociation rate constant of the COMT–opicapone complex.Conclusion: Despite its short elimination half‐life, opicapone markedly and sustainably inhibited erythrocyte S‐COMT activity making it suitable for a once daily regimen.

18 December 2012 in Clinical Pharmacokinetics
Verified
Journal Article
Closed access
PDF file
LALuis Almeida
Luis Almeida
JRJosé Francisco Rocha
José Francisco Rocha
AFAmílcar Falcão
Amílcar Falcão
PPP. Nuno Palma
P. Nuno Palma
ALAna I. Loureiro
Ana I. Loureiro
PSPatrício Soares-Da-Silva
Patrício Soares-Da-Silva

11 May 2000 in Proteins: Structure, Function, and Bioinformatics
Verified
Journal Article
Closed access
PDF file
PPP. Nuno Palma
P. Nuno Palma
LKLudwig Krippahl
Ludwig Krippahl
JWJohn E. Wampler
John E. Wampler
Jose J. G. MouraJose J. G. Moura
Jose J. G. Moura